Protagonist Therapeutics price target raised to $54 from $50 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...